Clinical Significance of T2-Weighted Sequence Intensity on Magnetic Resonance Imaging in Clinically Non-Functioning Pituitary Adenomas

Abstract

Background Little is known about the relationship between signal intensity patterns on T2-weighted magnetic resonance imaging (MRI) in non-functioning pituitary adenomas (NFPAs).

Objective In this study, the clinical, hormonal, histological features, and therapeutic responses were evaluated according to the T2 signal intensity in NFPAs.

Methods This retrospective and multicenter study included a group of 166 NFPA patients (93 men, 56%, mean age 58.5 ±14.8 yr).

Results: Approximately half of the tumors (n=84, 50.6%) were hyperintense, while 34.3% (n=57) and 15.1% (n=25) were iso- and hypointense, respectively. The median maximum tumor diameter of the isointense group [16 (13–25) mm] was significantly lower than that of the hyperintense [23 (16.6–29.7) mm] group (p=0.003). Similarly, the tumor volume of the isointense group [1,523 (618–5,226) mm³] was significantly lower than that of the hyperintense [4,012 (2,506–8,320) mm³] group (p=0.002). Chiasmatic compression occurred less frequently in tumors with isointense signal characteristics (38.6%) compared to tumors with hypointense (68%) and hyperintense (65.5%) signal characteristics (p=0.003). Invasive adenomas (p=0.001) and the degree of cavernous sinus invasion (p<0.001) were more frequent in the hyperintense adenoma group compared to the remaining groups. Plurihormonal tumors and silent lactotroph adenomas were more frequent in the isointense tumor group.

Conclusion In conclusion, hyperintensity on T2-weighted MRI in NFPAs is associated with larger and more invasive tumors compared to isointense NFPAs.

Key words

nonfunctioning pituitary adenoma - T2-weighted magnetic resonance imaging - clinical outcome

Publication History

Received: 09 August 2023
Received: 19 September 2023

Accepted: 17 October 2023

Article published online:
06 December 2023

• References

• 1 Gruppetta M. A current perspective of pituitary adenoma MRI characteristics: A review. Expert Rev Endocrinol Metab 2022; 17: 499-511 DOI: 10.1080/17446651.2022.2144230.
• 2 Fajardo-Montañana C, Villar R, Gómez-Ansón B. et al. Recommendations for the diagnosis and radiological follow-up of pituitary neuroendocrine tumours. Endocrinol Diabetes Nutr (Engl Ed) 2022; 69: 744-761 DOI: 10.1016/j.endien.2021.10.014.
• 3 Puig-Domingo M, Resmini E, Gomez-Anson B. et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab 2010; 95: 4973-4978 DOI: 10.1210/jc.2010-0573.
• 4 Potorac I, Petrossians P, Daly AF. et al. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr Relat Cancer 2016; 23: 871-881 DOI: 10.1530/ERC-16-0356.
• 5 Alhambra-Expósito MR, Ibáñez-Costa A, Moreno-Moreno P. et al. Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas. Sci Rep 2018; 8: 6173 DOI: 10.1038/s41598-018-24260-y.
• 6 Bonneville JF. A plea for the T2W MR sequence for pituitary imaging. Pituitary 2019; 22: 195-197 DOI: 10.1007/s11102-018-0928-9.
• 7 Coopmans EC, Schneiders JJ, El-Sayed N. et al. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. Eur J Endocrinol 2020; 182: 595-605 DOI: 10.1530/EJE-19-0840.
• 8 Karavitaki N, Thanabalasingham G, Shore HC. et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxf) 2006; 65: 524-529 DOI: 10.1111/j.1365-2265.2006.02627.x.
• 9 Knosp E, Steiner E, Kitz K. et al. Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993; 33: 610-617 DOI: 10.1227/00006123-199310000-00008.
• 10 Potorac I, Petrossians P, Daly AF. et al. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer 2015; 22: 169-177 DOI: 10.1530/ERC-14-0305.
• 11 Greenman Y, Cooper O, Yaish I. et al. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol 2016; 175: 63-72 DOI: 10.1530/EJE-16-0206.
• 12 Hagiwara A, Inoue Y, Wakasa K. et al. Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: Imaging characteristics and pathologic correlation. Radiology 2003; 228: 533-538 DOI: 10.1148/radiol.2282020695.
• 13 Bakhtiar Y, Hanaya R, Tokimura H. et al. Geometric survey on magnetic resonance imaging of growth hormone producing pituitary adenoma. Pituitary 2014; 17: 142-149 DOI: 10.1007/s11102-013-0479-z.
• 14 Gruppetta M, Vassallo J. Epidemiology and radiological geometric assessment of pituitary macroadenomas: Population-based study. Clin Endocrinol (Oxf) 2016; 85: 223-231 DOI: 10.1111/cen.13064.
• 15 Zada G, Lin N, Laws ER. Patterns of extrasellar extension in growth hormone-secreting and nonfunctional pituitary macroadenomas. Neurosurg Focus 2010; 29: E4 DOI: 10.3171/2010.7.FOCUS10155.
• 16 Cazabat L, Dupuy M, Boulin A. et al. Silent, but not unseen: Multimicrocystic aspect on T2-weighted MRI in silent corticotroph adenomas. Clin Endocrinol (Oxf) 2014; 81: 566-572 DOI: 10.1111/cen.12443.
• 17 Kasuki L, Antunes X, Coelho MCA. et al. Accuracy of microcystic aspect on T2-weighted MRI for the diagnosis of silent corticotroph adenomas. Clin Endocrinol (Oxf) 2020; 92: 145-149 DOI: 10.1111/cen.14133.
• 18 Gruppetta M, Formosa R, Falzon S. et al. Expression of cell cycle regulators and biomarkers of proliferation and regrowth in human pituitary adenomas. Pituitary 2017; 20: 358-371 DOI: 10.1007/s11102-017-0803-0.
• 19 Burlacu MC, Maiter D, Duprez T. et al. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists. Endocrine 2019; 63: 323-331 DOI: 10.1007/s12020-018-1765-3.
• 20 Pierallini A, Caramia F, Falcone C. et al. Pituitary macroadenomas: preoperative evaluation of consistency with diffusion-weighted MR imaging--initial experience. Radiology 2006; 239: 223-231 DOI: 10.1148/radiol.2383042204.
• 21 Nie D, Zhao P, Li C. et al. Application of "mosiac sign" on T2-WI in predicting the consistency of pituitary neuroendocrine tumors. Front Surg 2022; 9: 922626 DOI: 10.3389/fsurg.2022.922626.
• 22 Yiping L, Ji X, Daoying G. et al. Prediction of the consistency of pituitary adenoma: A comparative study on diffusion-weighted imaging and pathological results. J Neuroradiol 2016; 43: 186-194 DOI: 10.1016/j.neurad.2015.09.003.
• 23 Mastorakos P, Mehta GU, Chatrath A. et al. Tumor to cerebellar peduncle T2-Weighted imaging intensity ratio fails to predict pituitary adenoma consistency. J Neurol Surg B Skull Base 2019; 80: 252-257 DOI: 10.1055/s-0038-1668516.